Systemic sclerosis & Raynaud's
Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series
Authors' conclusion
Anti-CD19 CAR-T therapy was well tolerated and associated with clinical and radiological improvement in SSc patients relapsing after AHSCT.
Study context
- Population
- Female patients with SSc relapsing after autologous haematopoietic stem cell transplantation (AHSCT) (relapse: Modified Rodnan skin score (mRSS) increase ≥25% or forced vital capacity (FVC) decrease ≥10%); mean age 50 ± 13 yearsof 30 AHSCT patients
- Participants
- 3 patients
- Outcome
- Clinical response over 12 months
- Follow-up
- 12 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Favourable clinical response with FVC improvement (≥10%) and ≥25% reduction in mRSS, with reduced ground-glass opacities on CT
2
No CAR-T expansion and no clinical response
1
Observational data: associations, not effects.
Safety
Adverse events
- Mild, limited to grade 1 cytokine release syndrome and one line-related thrombosis
- No long-term haematological toxicity
Original publication
Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series. Rheumatology (Oxford). Published 4 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →